Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

ClinicalTrials.gov ID: NCT03175172

Public ClinicalTrials.gov record NCT03175172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma

Study identification

NCT ID
NCT03175172
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aduro Biotech, Inc.
Industry
Enrollment
10 participants

Conditions and interventions

Interventions

  • CRS-207 Biological
  • Pembrolizumab Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 30, 2017
Primary completion
Jan 8, 2018
Completion
Jan 30, 2018
Last update posted
Apr 3, 2019

2017 – 2018

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
UCSF Comprehensive Cancer Center San Francisco California 94115
H. Lee Moffitt Cancer Center Tampa Florida 33612
University of Chicago Medical Center Chicago Illinois 60637
NIH National Cancer Institute Bethesda Maryland 20892
Mayo Clinic Rochester Minnesota 55905
Laura & Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016
Cleveland Clinic Foundation Cleveland Ohio 44195
Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03175172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03175172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →